Syngene International Ltd Stock Falls to 52-Week Low of Rs.476.8

Stock Performance and Market Context

On 28 Jan 2026, Syngene International Ltd (Stock ID: 197397), a key player in the Healthcare Services sector, recorded an intraday low of Rs.476.8, down 2.45% on the day. This price represents the lowest level the stock has traded at in the past 52 weeks, underscoring a sustained period of weakness. The stock has been on a consecutive decline for the last 10 trading sessions, resulting in a cumulative loss of 24.51% over this period.

In comparison, the Sensex index rose by 0.46% to close at 82,231.54, buoyed by gains in mega-cap stocks. The Sensex remains 4.78% below its 52-week high of 86,159.02, while Syngene’s stock has diverged sharply, delivering a negative return of 34.91% over the past year. This stark contrast highlights the stock’s relative underperformance within the broader market environment.

Further technical indicators reveal that Syngene is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning signals persistent downward momentum and a lack of near-term price support.

Financial Performance and Valuation Metrics

Syngene International’s recent quarterly results have contributed to the stock’s subdued performance. For the quarter ended December 2025, the company reported a Profit Before Tax Less Other Income (PBT LESS OI) of Rs.83.60 crores, reflecting a decline of 37.8% compared to the average of the previous four quarters. Net Profit After Tax (PAT) for the same period stood at Rs.52.29 crores, down 55.3% relative to the prior four-quarter average. Earnings Per Share (EPS) also hit a low of Rs.0.37, marking the weakest quarterly EPS in recent periods.

Over the last five years, Syngene’s net sales have grown at an annualised rate of 11.77%, while operating profit has expanded at a more modest 5.36% per annum. These growth rates are below expectations for a company in the healthcare services sector, which has generally seen stronger expansion trends.

From a valuation standpoint, the company’s Return on Equity (ROE) is 9.9%, which, combined with a Price to Book Value (P/BV) ratio of 4.2, indicates a relatively expensive valuation. This premium is notable given the company’s recent earnings contraction and slower growth trajectory. The stock’s valuation is elevated compared to its peers’ historical averages, which may be contributing to the market’s cautious stance.

Long-Term and Relative Performance

Syngene International’s stock has underperformed not only in the short term but also over longer horizons. The stock’s one-year return of -34.91% contrasts sharply with the Sensex’s positive 8.34% return over the same period. Additionally, the stock has lagged the BSE500 index over the last three years, one year, and three months, indicating persistent challenges in delivering market-beating returns.

Despite these headwinds, the company maintains a low average Debt to Equity ratio of zero, reflecting a conservative capital structure with minimal leverage. Institutional investors hold a significant 40.8% stake in the company, suggesting that well-resourced market participants continue to maintain exposure despite recent price declines.

Mojo Score and Analyst Ratings

MarketsMOJO assigns Syngene International a Mojo Score of 28.0, categorising it with a Strong Sell grade as of 19 Jan 2026. This represents a downgrade from the previous Sell rating, reflecting deteriorating fundamentals and valuation concerns. The company’s Market Cap Grade stands at 3, indicating a mid-tier market capitalisation relative to other listed entities.

The downgrade to Strong Sell is driven by the combination of declining profitability, subdued growth rates, and stretched valuation multiples. These factors have weighed on investor sentiment and contributed to the stock’s recent price weakness.

Summary of Key Metrics

To summarise, Syngene International Ltd’s stock has reached a 52-week low of Rs.476.8 after a sustained period of decline. The stock has underperformed its sector and the broader market, with a 10-day consecutive fall resulting in a 24.51% loss. Financial results for the December 2025 quarter showed significant declines in profit metrics, while long-term growth rates remain modest. Valuation remains elevated relative to peers, with a high Price to Book ratio and moderate Return on Equity. Institutional holdings remain substantial, and the company maintains a low debt profile.

These factors collectively explain the stock’s current price level and the cautious market stance reflected in its Strong Sell rating by MarketsMOJO.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →